All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
59 results for "Cancer" and "Head and Neck Cancers"
Phase 1/2 Study Of REGN4336 (A PSMAXCD3 Bispecific Antibody) Administered Alone Or In Combination With Cemiplimab In Patients With Metastatic Castration-Resistant Prostate Cancer
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Protocol No
ALLIANCE-A011801
Sub Category
A Phase I Study of Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
Protocol No
IIT-AWAN-HART-HN
Sub Category
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
This study is for persons with recurrent glioblastoma that has failed to respond to or has come back after standard radiotherapy and Temozolomide treatment. The overall goal of this study is to develop Gallium Maltolate (GaM), an experimental drug, as a new oral treatment for patients with glioblastoma brain tumors whose tumor has relapsed after initial treatment or has progressed despite initial treatment.
Protocol No
IIT-CONNELLY-GBM-GAMAY
Sub Category
Bicycle-BT5528-100 Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
This study is a Phase I/II, first-in-human, open-label dose-escalation study of BT5528 given as a single agent (Parts A-1 and B-1) and in combination with nivolumab (Parts A-2 and B-2). There are two parts to this study: Part A, dose escalation and Part B, dose expansion.
Protocol No
BICYCLE-BT5528-100
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer (INNOVATE)
Protocol No
NRG-GU008-INNOVATE
Sub Category
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Protocol No
JOUNCE-JTX-8064-101
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Niraparib with Standard Combination RT & ADT in Treating Patients With High Risk Prostate Cancer
Protocol No
NRG-GU007
Sub Category
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Protocol No
ECOG-EA3191
Sub Category
Optimizing NeuroCOgnition with Whole Brain Radiation Therapy (WBRT) using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole Brain Radiation Therapy for Brain Metastases
This project is being done to test a new technique called pulsed reduced dose-rate
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
Protocol No
IIT-SAEED-ONCO-RT
Sub Category
A Phase II Trial of OnapriStone in CoMbInation with FuLvestrant for Patients with ER-positive, and HER2-negative Metastatic Breast Cancer after Progression on Endocrine Therapy and CDK 4/6 inhibitors
This study will find out if a drug called onapristone, in combination with fulvestrant, can stop or slow metastatic breast cancer.
Protocol No
WON-UW20037-SMILE-ONAPRISTONE
Sub Category
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Protocol No
AFT-47-ARACOG
Sub Category
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Protocol No
IIT-MENON-COINCIDE
Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)
This project is being done to to assess the efficacy of substituting Pulsed Reduced Dose
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Protocol No
IIT-STRAZA-PRORADGLIO
Sub Category
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)
Protocol No
CCTG-MA-39-TAILOR-RT
Sub Category
A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation
To investigate how HB-201 affects the immune response
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
Protocol No
HOOKIPA-H-200-002
Sub Category
Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination with BI 754091 in Solid Tumors
To characterize the safety and to determine the maximum tolerated dose (MTD) for BI 1387446 in combination with ezabenlimab (BI 754091).
Protocol No
BI-1426-0001
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
Protocol No
IIT-AWAN-NIH-DEHART
Sub Category